Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13016528 | 0.92 | ACHE (0.67) | ACHEOPRM1OPRK1OPRL1DRD2 | |
| SCHEMBL10485607 | 0.91 | ACHE (0.59) | ACHEOPRM1OPRK1OPRL1DRD2 | |
| SCHEMBL5633429 | 0.91 | ACHE (0.59) | ACHEOPRM1OPRK1OPRL1DRD2 | |
| SCHEMBL8327851 | 0.88 | ACHE (0.57) | ACHEDRD2CHRM3 | |
| SCHEMBL7624980 | 0.88 | ACHE (0.57) | ACHE | |
| SCHEMBL7240237 | 0.88 | ACHE (0.69) | ACHEOPRM1OPRK1OPRL1DRD2 | |
| SCHEMBL15847630 | 0.84 | DRD2 (0.68) | ACHEOPRM1OPRK1OPRL1DRD2 | |
| SCHEMBL7429758 | 0.83 | ACHE (0.57) | ACHEOPRM1OPRK1OPRL1CHRM3 | |
| SCHEMBL3075361 | 0.83 | OPRL1 (0.66) | ACHEOPRM1OPRK1OPRL1DRD2 | |
| SCHEMBL28478268 | 0.82 | PARP1 (0.58) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113668004-B | Method for electrochemical synthesis of non-natural amino acid derivatives | 浙江工业大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-113668004-A | Method for electrochemically synthesizing non-natural amino acid derivatives | 浙江工业大学 | 2021-11-19 | — | — | CN | disclosed |
| EP-2188251-B1 | ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2015-04-29 | — | — | EP | disclosed |
| EP-2061779-B1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INT (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2402329-B1 | Analgetic phenylsulphonamides | BOEHRINGER INGELHEIM INT (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| EP-2402329-A1 | Analgetic phenylsulphonamides | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294775-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-2284166-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2011-02-16 | — | — | EP | disclosed |
| US-6492365-B1 | Microsomal triglyceride transfer protein | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6066650-A | USEFUL FOR LOWERING SERUM LIPIDS AND TREATING ATHEROSCLEROSIS AND RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-23 | — | — | US | disclosed |
| US-6034098-A | ATHEROSCLEROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-07 | — | — | US | disclosed |
| US-5883099-A | TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| US-5789197-A | GENETIC ENGINEERING | E. R. SQUIBB & SONS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5739135-A | PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| US-5595872-A | DNA SEQUENCES, CELLS AND EXPRESSION VECTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| WO-1996026205-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-29 | — | — | WO | disclosed |
| EP-0643057-A1 | Inhibitors of microsomal triglyceride transfer protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-15 | — | — | EP | disclosed |
| US-4291042-A | ANTIINFLAMMATORY AGENTS, ANTICONVULSANTS, ANTIARRHYTHMIA AGENTS | JOHN WYETH & BROTHER LIMITED (GB) | 1981-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294775-A1 | NOVEL COMPOUNDS | TRPV1, OPRL1, TRPA1 | ACHE 171/4885OPRM1 55/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.